Table 1

Changes in clinical assessments, bone mineral density and laboratory analysis following anti-TNF treatment in AS patients

Baseline

6 months

12 months

P


BASDAI

5.11 ± 2.1

2.78 ± 2.4

2.78 ± 2.5

< 0.001

BASFI

5.40 ± 2.7

2.96 ± 2.6

2.85 ± 2.7

< 0.001

BASMI

4.06 ± 2.7

3.23 ± 2.6

3.07 ± 2.7

0.003

AsQoL, score

10.03 ± 5.2

6.43 ± 6.4

6.40 ± 6.05

0.001

ESR, mm/hr

23.75 ± 23.1

8.16 ± 15.6

7.3 ± 13.1

< 0.001

C-reactive protein, mg/dL

37.03 ± 47.9

3.35 ± 4.1

7.21 ± 20.1

< 0.001

MMP-3, ng/mL

48.6 ± 42.5

21.6 ± 22.5

23.3 ± 30.8

< 0.001

BMD lumbar spine, g/cm2

1.032 ± 0.175

1.049 ± 0.169

1.065 ± 0.169

< 0.001

BMD femoral neck, g/cm2

0.864 ± 0.160

0.865 ± 0.159

0.864 ± 0.161

0.051

BMD total femur, g/cm2

0.990 ± 0.165

0.986 ± 0.165

0.999 ± 0.171

0.981

Sclerostin, pmol/L

60.5 ± 32.7

67.1 ± 31.9

72.7 ± 32.3

< 0.001

Sclerostin binding to LRP6, OD450

0.61 ± 0.13

ND

0.60 ± 0.14

0.472


Values are expressed as mean (SD). AS, ankylosing spondylitis; BASDAI, Bath AS Disease Activity Index; BASFI, Bath AS Functional Index; BASMI, Bath AS Metrology Index; ASQoL, AS quality of life questionnaire; BMD, bone mineral density; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase 3; LRP6, low-density lipoprotein receptor-related protein 6; OD, optical density; ND, not done.

Saad et al. Arthritis Research & Therapy 2012 14:R216   doi:10.1186/ar4055

Open Data